Artelo Biosciences Q2 Earnings: $5.61 EPS, FABP5 Inhibitor Pipeline Advances

Artelo Biosciences reported Q2 EPS of ($5.61), up from ($4.52) last year. The company's President and CEO, Gregory D. Gorgas, highlighted the growing evidence supporting their first-in-class FABP5 inhibitor, ART26.12, and their plans to report Phase 2 data from their CAReS study of ART27.13 during Q3. Artelo is also on track to collect data on their preclinical candidate ART12.11 for treating depression and cognitive decline.

Artelo Biosciences Inc (ARTL) reported a quarterly adjusted loss of $5.61 per share for the quarter ended June 30, 2025, marking an improvement from the same quarter last year when the company reported EPS of $-4.50 [1]. The lone analyst forecast for the quarter was for a loss of $4.19 per share. The company's President and CEO, Gregory D. Gorgas, highlighted the growing evidence supporting their first-in-class FABP5 inhibitor, ART26.12, and their plans to report Phase 2 data from their CAReS study of ART27.13 during Q3. Artelo is also on track to collect data on their preclinical candidate ART12.11 for treating depression and cognitive decline.

The company reported a quarterly loss of $3.22 million, with revenue remaining at zero. Analysts expected zero revenue for the quarter. The company's shares fell by 26.8% this quarter and gained 52.8% so far this year. The mean earnings estimate of analysts had fallen by about 437.2% in the last three months, with no revisions in the last 30 days [1].

The current average analyst rating on the shares is "buy," with no "hold" or "sell" recommendations. The average consensus recommendation for the biotechnology & medical research peer group is also "buy." Wall Street's median 12-month price target for Artelo Biosciences Inc is $24.00, about 59.5% above its last closing price of $9.72 [1].

Artelo Biosciences Inc's reported EPS for the quarter was a loss of $5.61, missing the analyst estimate of $-4.19. The company has consistently missed analyst estimates in the past quarters, including Q1 2025 where it reported EPS of $-4.32, and Q4 2024 where it reported EPS of $-7.02 [1].

In contrast, NRx Pharmaceuticals (NASDAQ:NRXP) has received FDA Fast Track designation for NRX-100, its intravenous ketamine treatment for suicidal ideation in patients with depression, including bipolar depression. This designation represents a significant market opportunity, addressing approximately 13 million Americans who consider suicide annually. The company targets a $3+ billion market opportunity, with a potential three-year room temperature shelf life for their preservative-free ketamine formulation [2].

References:
[1] https://www.tradingview.com/news/reuters.com,2025:newsml_L8N3U50U8:0-artelo-biosciences-inc-reports-results-for-the-quarter-ended-june-30-earnings-summary/
[2] https://www.stocktitan.net/news/NRXP/n-rx-pharmaceuticals-inc-nasdaq-nrxp-granted-fda-fast-track-ayetxan1s6b6.html